BACKGROUND Respiratory viruses are increasingly detected in children with communityacquired pneumonia.Further strategies to limit antibiotic use in children with viral pneumonia are warranted.AIM To explore clinical e...BACKGROUND Respiratory viruses are increasingly detected in children with communityacquired pneumonia.Further strategies to limit antibiotic use in children with viral pneumonia are warranted.AIM To explore clinical efficacy of budesonide/formoterol inhalation powder for viral pneumonia in children and its impact on cellular immunity and inflammatory factor production.METHODS A total of 60 children with viral pneumonia were recruited:30 receiving budesonide/formoterol inhalation powder and 30 conventional symptomatic treatment.Outcome measures included peripheral blood levels of inflammatory cytokines,CD4^(+),CD8^(+),Th1,Th2,Th17 and Treg,clinical efficacy,and incidence of adverse reactions.RESULTS Compared with the control group,the observation group showed a significant reduction in interleukin-6 and high-sensitivity C-reactive protein levels after treatment.Compared with the control group,the observation group showed a significant increase in CD4^(+)/CD8^(+)and Th1/Th2 levels,and a decrease in Th17/Treg levels after treatment.The total effective rates in the observation group and the control group were 93.75%and 85.00%,respectively,which was a significant difference(P=0.003).CONCLUSION Budesonide/formoterol inhalation powder significantly improved therapeutic efficacy for viral pneumonia in children.The mechanism of action may be related to downregulation of the inflammatory response and improved cellular immune function.展开更多
目的探究布地奈德/福莫特罗粉吸入剂(信必可)联合无创正压通气治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)伴II呼吸衰竭的临床效果价值。方法选取2016-06至2017-03在包头市...目的探究布地奈德/福莫特罗粉吸入剂(信必可)联合无创正压通气治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)伴II呼吸衰竭的临床效果价值。方法选取2016-06至2017-03在包头市中心医院住院治疗的AECOPD伴呼吸衰竭作为研究对象,采用随机表法分为对照组和试验组,对照组采取沙丁胺醇联合无创正压通气,试验组采用信必可联合无创正压通气,收集两组患者治疗前及治疗后健康相关生活质量圣乔治呼吸问卷(St Georges respiratory questionnaire,SGRQ)评分、呼吸困难量表(modified medical research council,mMRC)评分、氧代谢、肺功能、6 min步行测试(six-minute walk test,6MWT)和痰IL-8指标进行统计学分析。结果试验组有效率:96.97%,对照组有效率:75.76%,两组间比较有统计学差异(P=0.04);试验组中SGRQ评分、mMRC评分、氧代谢指标、肺通气及换气指标、6MWT、痰IL-8指标均优于对照组,两组间比较均有统计学差异(P<0.05)。结论布地奈德/福莫特罗粉吸入剂联合无创正压通气治疗能有效改善AECOPD伴呼吸衰竭患者呼吸困难症状,改善肺功能、氧代谢指标,提高患者生活质量,临床值得应用。展开更多
目的:探讨布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期患者的临床效果。方法:选取2021年1月—2023年6月就诊于镇宁布依族苗族自治县人民医院呼吸与危重症医学科的60例慢性胃炎患者为研究对象。采用随机数表法将患者分为两组,各3...目的:探讨布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期患者的临床效果。方法:选取2021年1月—2023年6月就诊于镇宁布依族苗族自治县人民医院呼吸与危重症医学科的60例慢性胃炎患者为研究对象。采用随机数表法将患者分为两组,各30例。对照组患者接受布地奈德福莫特罗吸入粉雾剂治疗,观察组患者接受布地格福吸入气雾剂治疗,对两组患者临床治疗效果进行对比。结果:治疗后,观察组第1秒用力呼气容积(forced expiratory volume in one second,FEV1)、用力肺活量(forced vital capacity,FVC)、呼气峰值流速(peak expiratory flow,PEF)明显高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为3.33%,对照组不良反应发生率为13.33%,观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为96.67%,对照组治疗总有效率为80.00%,观察组高于对照组,差异有统计学意义(P<0.05)。结论:与布地奈德福莫特罗吸入粉雾剂比较,布地格福吸入气雾剂在改善慢性阻塞性肺疾病急性加重期患者肺功能指标和降低不良反应发生率方面的临床效果更好。展开更多
基金the Wenzhou Basic Medical and Health Science and Technology Project,No.Y20210307.
文摘BACKGROUND Respiratory viruses are increasingly detected in children with communityacquired pneumonia.Further strategies to limit antibiotic use in children with viral pneumonia are warranted.AIM To explore clinical efficacy of budesonide/formoterol inhalation powder for viral pneumonia in children and its impact on cellular immunity and inflammatory factor production.METHODS A total of 60 children with viral pneumonia were recruited:30 receiving budesonide/formoterol inhalation powder and 30 conventional symptomatic treatment.Outcome measures included peripheral blood levels of inflammatory cytokines,CD4^(+),CD8^(+),Th1,Th2,Th17 and Treg,clinical efficacy,and incidence of adverse reactions.RESULTS Compared with the control group,the observation group showed a significant reduction in interleukin-6 and high-sensitivity C-reactive protein levels after treatment.Compared with the control group,the observation group showed a significant increase in CD4^(+)/CD8^(+)and Th1/Th2 levels,and a decrease in Th17/Treg levels after treatment.The total effective rates in the observation group and the control group were 93.75%and 85.00%,respectively,which was a significant difference(P=0.003).CONCLUSION Budesonide/formoterol inhalation powder significantly improved therapeutic efficacy for viral pneumonia in children.The mechanism of action may be related to downregulation of the inflammatory response and improved cellular immune function.
文摘目的探究布地奈德/福莫特罗粉吸入剂(信必可)联合无创正压通气治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)伴II呼吸衰竭的临床效果价值。方法选取2016-06至2017-03在包头市中心医院住院治疗的AECOPD伴呼吸衰竭作为研究对象,采用随机表法分为对照组和试验组,对照组采取沙丁胺醇联合无创正压通气,试验组采用信必可联合无创正压通气,收集两组患者治疗前及治疗后健康相关生活质量圣乔治呼吸问卷(St Georges respiratory questionnaire,SGRQ)评分、呼吸困难量表(modified medical research council,mMRC)评分、氧代谢、肺功能、6 min步行测试(six-minute walk test,6MWT)和痰IL-8指标进行统计学分析。结果试验组有效率:96.97%,对照组有效率:75.76%,两组间比较有统计学差异(P=0.04);试验组中SGRQ评分、mMRC评分、氧代谢指标、肺通气及换气指标、6MWT、痰IL-8指标均优于对照组,两组间比较均有统计学差异(P<0.05)。结论布地奈德/福莫特罗粉吸入剂联合无创正压通气治疗能有效改善AECOPD伴呼吸衰竭患者呼吸困难症状,改善肺功能、氧代谢指标,提高患者生活质量,临床值得应用。
文摘目的:探讨布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期患者的临床效果。方法:选取2021年1月—2023年6月就诊于镇宁布依族苗族自治县人民医院呼吸与危重症医学科的60例慢性胃炎患者为研究对象。采用随机数表法将患者分为两组,各30例。对照组患者接受布地奈德福莫特罗吸入粉雾剂治疗,观察组患者接受布地格福吸入气雾剂治疗,对两组患者临床治疗效果进行对比。结果:治疗后,观察组第1秒用力呼气容积(forced expiratory volume in one second,FEV1)、用力肺活量(forced vital capacity,FVC)、呼气峰值流速(peak expiratory flow,PEF)明显高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为3.33%,对照组不良反应发生率为13.33%,观察组低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为96.67%,对照组治疗总有效率为80.00%,观察组高于对照组,差异有统计学意义(P<0.05)。结论:与布地奈德福莫特罗吸入粉雾剂比较,布地格福吸入气雾剂在改善慢性阻塞性肺疾病急性加重期患者肺功能指标和降低不良反应发生率方面的临床效果更好。
